Wellington Management Group
KYTX icon

Wellington Management Group’s Kyverna Therapeutics KYTX Stock Holding History

Wellington Management Group’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,828
Closed -$73K – 2072
2025
Q1 		$73K Sell
37,828
-236,586
-86% -$699K ﹤0.01% 1923
2024
Q4 		$1.03M Buy
274,414
+39,291
+17% +$188K ﹤0.01% 1713
2024
Q3 		$1.15M Sell
235,123
-478,277
-67% -$3.69M ﹤0.01% 1684
2024
Q2 		$5.35M Buy
713,400
+111,964
+19% +$1.71M ﹤0.01% 1301
2024
Q1 		$14.9M Buy
+601,436
New +$16.8M ﹤0.01% 1013

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MPM
MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group's KYTX Position: Q2 2025 in Review

Wellington Management Group sold out of Kyverna Therapeutics (KYTX) in Q2 2025, closing a stake of 37,828 shares — an estimated $73K sold.

Wellington Management Group first reported a position in KYTX in Q1 2024 and held it in 5 quarters. The position peaked at $14.9M in Q1 2024. 79 funds tracked by Wall St. Rank hold KYTX as of Q2 2025.

  • Wellington Management Group reported no remaining Kyverna Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wellington Management Group sold 37,828 Kyverna Therapeutics shares in Q2 2025, an estimated $73K.
  • Wellington Management Group first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 5 quarters.
  • Wellington Management Group's Kyverna Therapeutics position peaked at $14.9M in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2025.

Based on Wellington Management Group's 13F filing for Q2 2025, filed 14 Aug 2025.